Interestingly, agonistic targeting of VISTA has recently been proposed as a potential strategy to alleviate Chimeric Antigen Receptor (CAR) T-cell-induced CRS through myeloid compartment modulation40. This evidence concerns the gene VSIR and congenital rubella syndrome.